Citigroup analyst David Lebovitz initiates coverage on Crinetics Pharmaceuticals (NASDAQ:CRNX) with a Buy rating and announces Price Target of $68.
Citigroup Initiates Coverage On Crinetics Pharmaceuticals With Buy Rating, Announces Price Target of $68
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.